Tactile and Visual Hallucinations in a Child With Methylphenidate and Fluoxetine Combination

Journal of clinical psychopharmacology (Impact Factor: 3.24). 01/2009; 28(6):723-5. DOI: 10.1097/JCP.0b013e31818ce752
Source: PubMed
Download full-text


Available from: Murat Coskun, Jun 07, 2014

  • Anales de Pediatría 03/2010; 72(3):229-230. DOI:10.1016/j.anpedi.2009.10.013 · 0.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review of the 2010 publications on adverse reactions to central nervous system stimulants and drugs that suppress appetite covers amphetamines (amfetamine, dexamfetamine, and metamfetamine), benfluorex (in a special review), atomoxetine, methylphenidate, modafinil, methylxanthines (caffeine and theobromine), phentermine, sibutramine, rimonabant, tesofensine, and drugs used in Alzheimer's disease (donepezil, memantine, and rivastigmine). Benfluorex, an appetite suppressant structurally related to fenfluramine, was used for the management of obesity and to improve glycemic control and reduce insulin resistance in patients with poorly controlled type 2 diabetes mellitus. It has been estimated that several million people were exposed to benfluorex before its recent withdrawal because of adverse reactions. Cases of valvular heart disease and cases of pulmonary hypertension associated with benfluorex are reviewed. Other stimulants, such as methylphenidate, used in the treatment of attention deficit hyperactivity disorder, are discussed. Newer insights on methylxanthine toxicity due to genetic susceptibility and regulatory policy changes on sibutramine, in view of cardiovascular safety concerns, are reviewed. An update on drugs used in Alzheimer's disease is also provided.
    Side Effects of Drugs Annual 01/2011; 34(1). DOI:10.1016/S0378-6080(08)00001-9
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We report a case of a girl with Attention deficit hyperactivity disorder (ADHD) and Oppositional defiant disorder (ODD) who experienced a 3-hour episode of nocturnal complex bizarre visual hallucinations when treated with 18 mg Osmotic Release Oral System (OROS) methylphenidate (MPH). Nocturnal polysomnography performed two weeks later revealed REM sleep reduction (17%) and fragmentation . Two episodes of confusional arousals were recorded. This finding is typical of parasomnia associated with NREM sleep - disorder of arousal. We hypothesize that this preexisting sleep impairment represents a factor of vulnerability to MPH sleep side effects. In our search of literature, we found no report of nocturnal hallucination alone during treatment with stimulants.
    Neuro endocrinology letters 09/2011; 32(5):619-22. · 0.80 Impact Factor
Show more